is...(Checking in now and then!)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SO EXACTLY HOW DID YOU GET THIS INFO. WE KNOW IT WAS NOT A CALCULATED GUESS LOOKING AT THE CHARTS AND THE MOON MISS-ALIGNING WITH $RGBP. PLEASE TELL...
That would have happened along time ago if true. Try again dude
Thanks for all keeping the facts in order..
CONFIRMATION NEWS YESYERDAY.
NO kidding bought 12 milly the other day.. great investment here.. $Rgbp
POSITIVE!! I SOLD IT ALL FOR THIS.. MASSIVE GAINS ALREADY.
like arm wrestling here bulls are back!
AGREED... UP UP WE GO...
Looks like .045 was support heading north....
And Cure Cancer at the SAME TIME...
Were Vested In Multi CURES FOR CANCER....YES!
Great Investment welcome!
BUY.BUY..BUY...HOLD...HOLD...FOR...GOLD...
Thanks for that great DD
My TDA showing 41% gain premarket..
I hope you Mean .039 Pivot Point..LOL
Main Patent Targeting Cancer..If interested..Solid Close coming!
From there site. https://www.regenbiopharmainc.com/products.html
Small Molecules Targeting Cancer and Autoimmunity
Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls
how the immune system reacts to cancer cells and to inflammatory responses.
Objective is to identify small molecules that can activate and inhibit NR2F6
?Currently in pre-clinical development
Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
Additional indications include solid tumors, acute leukemia and GVHD
____________________________________________________________________________
Googles page https://patents.google.com/patent/US9091696B2/en
PDF of patent https://patentimages.storage.googleapis.com/c1/c4/8e/b433df0914cc1f/US9091696.pdf
Modulation of NR2F6 and methods and uses thereof.
The invention claimed is:
1. A method for identifying compounds that can modulate the function of NR2F6 in mammalian cells comprising the steps of:
(i) selecting a cancer (a) cell line or (b) cell-free lysate to use;
(ii) expressing in the cancer cell-line or cell-free lysate proteins encoded by one or more recombinant DNA vectors that comprise a reporter assay system, having a portion of the gene with SEQ ID NO:1 that has been predetermined to control the transcriptional activity of the gene NR2F6 and that encodes for expression of an amino acid sequence of at least 75% sequence identity to a portion of the amino acid sequence of SEQ ID NO: 2;
(iii) contacting the cancer cell-line or or cell-free lysate with a candidate compound;
(iv) measuring the ability of the candidate compound to inhibit or stimulate said reporter assay system; and
(v) comparing the measurement of the ability of the candidate compound to inhibit or stimulate said reporter assay system with a suitable control so as to determine whether said inhibition or stimulation of said reporter assay system is indicative of a compound for modulating the function of NR2F6 in a mammal.
2. The method of claim 1 wherein HeLa cells are used for the cancer (a) cell-line or (b) cell-free lysate.
3. The method of claim 1, wherein the method is a high-throughput screening.
4. The method of claim 1, wherein the portion of the nucleotide that encodes for expression of an amino acid sequence of at least 75% sequence identity of the amino acid sequence of SEQ ID NO: 2 is the ligand binding domain of NR2F6.
5. The method of claim 1, wherein the reporter assay system measures the ability of the candidate compound to cause a conformational change in the ligand binding domain of NR2F6.
6. The method of claim 1, wherein the reporter assay system measures the compound's ability to modulate the ability of NR2F6 to repress or activate transcription.
7. The method of claim 1 wherein a cell based assay is used in which the host cell contains an expression vector, said expression vector comprising a polynucleotide, said polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
8. The method of claim 1 wherein a cell based assay using cultured mammalian cells transfected with a vector encoding for a protein with amino acid sequence of SEQ ID NO: 2 and a reporter construct, where the cells are treated with candidate compounds and assessed for the activity of the reporter construct.
9. The method of claim 1 wherein the reporter assay system consists of at least one or more DNA vectors, one of which contains a DNA binding site positioned adjacent to an expressible reporter element; another contains a chimeric transactivatable vector comprising nucleotides that encode for a portion of the NR2F6 gene and a DNA binding domain that specifically binds to the DNA binding site.
10. The method of claim 9 wherein the DNA binding site further comprises a GAL4 binding element.
11. The method of claim 9 wherein the expressible reporter element is luciferase.
12. A method of claim 9 wherein the DNA binding domain that specifically binds to the DNA binding site consists of multiple Gal4 Upstream Activator Sequences.
MY2BITS
Annual Report For the Period Ending: December, 31, 2020?
https://backend.otcmarkets.com/otcapi/company/financial-report/275841/content
Annual fins been posted...
https://backend.otcmarkets.com/otcapi/company/financial-report/275841/content
Ihub trades shows 200k buy at .003 already. Good day ahead... Gap up?
MY2bits DD.. Our CEO @ $AMLH Mr.Adrian.P.Mckenzie Also CEO with DNA Brands PPS was down today from earlier pic below I did to 0.7704 close. Maybe we had investors jump ship over to here! LOL
Best I can Explain is my own DD from this previous post I did.
It basically says..
In the December 17, 2018 Shareholder Update Mr Mckenzie says
"My next task at hand, is to begin working with the various regulators, states, and OTC Markets to position American Leisure Holdings to become “OTC Current “and to also look to recruit exceptional talent." Adrian Mackenzie
--------------------------In two recent Tweets
AMLH Twitter page
I Called it LOL... I new it was soon with all the loadin here. This does not need news!
To answer your Question.. December 17, 2018 with the
Shareholder Update
He Says
"My next task at hand, is to begin working with the various regulators, states, and OTC Markets to position American Leisure Holdings to become “OTC Current “and to also look to recruit exceptional talent." Adrian Mackenzie
He is also CEO of $DNAX DNA Brands, Inc.
https://www.otcmarkets.com/stock/DNAX/profile
He also has PBDC LLC in florida that owns the company Domain name AMLH.net that every one is emailing.
search.sunbiz.org/Inquiry/CorporationSearch/
Going Current! I Have Faith in Him GLTA
$ITUP 8k News Super Thin From $9.50-$18
$TLSS Volume up moving this North!
MMs will eat up any stop losses set in here dont lose your shares. Hold for the moon with Diamond hands as they say!
PDS Biotech Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Ins...
Source: GlobeNewswire Inc.?
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the National Cancer Institute’s (NCI) Phase 2 clinical study of PDS0101 for the treatment of advanced human papillomavirus (HPV)-associated cancers that have progressed or returned after treatment achieved its preliminary objective response. The trial, which studies PDS0101 in combination with two investigational immune-modulating agents bintrafusp alfa (M7824), a TGF-ß “trap”/ anti-PD-L1 bifunctional fusion protein, and NHS-IL12 (M9241), a DNA-targeted immunocytokine, will now progress to full enrollment of approximately 20 in this group of checkpoint inhibitor (CPI) naïve patients. As a result of achieving this milestone, preliminary efficacy assessment of the triple combination in an added group of approximately 20 patients who have failed prior therapy with checkpoint inhibitors (CPI refractory) is ongoing.
The NCI Center for Cancer Research’s Laboratory of Tumor Immunology and Biology (LTIB) and Genitourinary Malignancies Branch (GMB) are jointly leading this Phase 2 trial. The trial is evaluating the treatment combination in two patient groups: one in patients who failed prior treatment, but are naïve to checkpoint inhibitor treatment; and the second in patients who have failed treatment with checkpoint inhibitors. As prespecified in the clinical trial design, the achievement of an objective response as measured by radiographic tumor responses according to RECIST 1.1 or iRECIST among at least three of the first eight patients allows the trial to progress to full enrollment.
Pooled data from phase 1 and 2 trials reported in the October 2020 issue of the Journal for Immunotherapy of Cancer (J ImmunoTher Cancer 2020;8:e001395. doi:10.1136/jitc-2020-001395) showed that bintrafusp alfa (M7824) a first-in-class bifunctional fusion protein composed of the extracellular domain of human TGF-ß (TGF-ß “trap”) fused to an IgG1 antibody blocking PD-L1 (anti–PD-L1) protein, demonstrated efficacy in checkpoint inhibitor-naïve patients with HPV-associated malignancies. The observed response rate was 30.5%. M9241 is an immunocytokine composed of 2 heterodimers of IL-12 fused to the heavy chains of a human antibody targeting DNA released from necrotic tumor cells. In preclinical studies performed at the NCI comparing each drug alone versus all three agents used in combination, the triple combination achieved the highest induction of tumor-specific CD8+ killer T-cells and superior antitumor effect (J ImmunoTher Cancer 2020;8:e000612. doi:10.1136/jitc-2020-000612).
“The achievement of this important milestone in this NCI-led Phase 2 clinical trial strengthens the evidence of our novel Versamune® platform’s potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer to achieve tumor regression,” commented Dr. Lauren Wood, Chief Medical Officer of PDS Biotech. “The initial data solidifies our belief that PDS0101’s demonstrated preclinical efficacy when combined with these two immune-modulating agents, has the potential to significantly improve clinical outcomes for patients with advanced and currently untreatable HPV-associated cancers.”
The studies are being performed as part of a Cooperative Research and Development Agreement (CRADA) between PDS Biotech and the NCI. Dr. Jeffrey Schlom, Chief, LTIB, and Dr. James Gulley, Chief, GMB, at NCI are serving as principal investigators for the NCI, while Dr. Frank Bedu-Addo and Dr. Lauren Wood, PDS Biotech’s Chief Executive Officer and Chief Medical Officer respectively, are serving as PDS Biotech’s investigators.
Dr. Julius Strauss, Staff Clinician, LTIB, is serving as the Principal Investigator of this phase 2 clinical trial in advanced HPV-associated cancers. For patients interested in enrolling in this clinical study, please call NCI’s toll-free number 1-800-4-CANCER (1-800-422-6237), email NCIMO_Referrals@mail.nih.gov, or visit the website: https://trials.cancer.gov.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
About PDS0101
PDS Biotech’s lead candidate, PDS0101, combines the utility of the Versamune® platform with targeted antigens in HPV-expressing cancers. In partnership with Merck and Co., PDS Biotech is studying a combination of PDS0101 and KEYTRUDA® to a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer. In separate partnership with the National Cancer Institute (NCI), and The University of Texas MD Anderson Cancer Center, PDS Biotech is conducting additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer respectively.
Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast.” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for its lead asset PDS0101; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Media & Investor Relations Contact:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com
Jacob Goldberger
CG Capital
Phone: +1 (404) 736-3841
Email: jacob@cg.capital
GOOD NEWS TO PUSH THIS TICKER ON UP! HAVE A GREAT DAY ALL...
FYI SHAREHOLDER ALERT:
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Northern Dynasty Minerals Ltd. of Class Action Lawsuit and Upcoming Deadline - NAK
NEWS PROVIDED BY
Pomerantz LLP
Jan 31, 2021, 05:00 ET
SHARE THIS ARTICLE
NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Northern Dynasty Minerals Ltd. ("Northern Dynasty" or the "Company") (NYSE: NAK) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-06126, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Northern Dynasty securities from December 21, 2017 through November 25, 2020, both dates inclusive (the "Class Period"). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder by the Securities and Exchange Commission.
If you are a shareholder who purchased Northern Dynasty securities during the Class Period, you have until February 2, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here for information about joining the class action]
Northern Dynasty engages in the exploration of mineral properties in the U.S. Its principal mineral property is the Pebble copper-gold-molybdenum project comprising 2,402 mineral claims that cover an area of approximately 417 square miles located in southwest Alaska (the "Pebble Project").
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company's business, operational, and compliance policies. Specifically, Defendants made false and/or misleading statements and failed to disclose to investors that: (i) the Company's Pebble Project was contrary to Clean Water Act guidelines and to the public interest; (ii) the Company planned that the Pebble Project would be larger in duration and scope than conveyed to the public; (iii) as a result, the Company's permit applications for the Pebble Project would be denied by the US Army Corps of Engineers ("USACE") and (iv) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
On August 24, 2020, the U.S. Army released a statement concerning the Pebble Project, stating that it would result in "significant degradation of the environment and would likely result in significant adverse effects on the aquatic system or human environment." The U.S. Army further found that "the project, as currently proposed, cannot be permitted under section 404 of the Clean Water Act." The U.S. Army requested that the Company submit a mitigation plan in response to this finding.
On this news, Northern Dynasty's common share price fell $0.55 per share, or 37.9%, to close at $0.90 per share on August 24, 2020.
On September 21, 2020, the Environmental Investigation Agency released a recording between investigators and Company executives that demonstrated that Northern Dynasty, contrary to previous public statements, actually planned to build a mine that would last up to 180 years.
On November 25, 2020, Northern Dynasty reported that the USACE had rejected its permit applications related to the Pebble Project.
On this news, Northern Dynasty's common share price fell $0.40 per share, or 50%, to close at $0.40 per share on November 25, 2020, damaging investors.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
SOURCE Pomerantz LLP
Related Links
www.pomerantzlaw.com
https://www.prnewswire.com/news-releases/shareholder-alert--pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-northern-dynasty-minerals-ltd-of-class-action-lawsuit-and-upcoming-deadline---nak-301218482.html
$SKDI .02 WOULD WORK FOR ME...
Yes and planned that way. They use auto listing and list majority of Auctions weekly on Thursdays about 5-7PM. This gives them all week to prepare the listings they want to sell for next Thursday. So at the same time listings are selling the new listings are going up for auction. A good way to do it and keep your sanity. Monday-Thursday to list Fridays to ship and still get weekends off! You can see this on the timestamp of each sale on the sold listings Here
News / Fins will get this moving good...
Yes Sir... some more interesting sales info. Only 16 of the total sales for the week were buy it now and the rest were auction items that start the bidding at .99 cents! With that in mind only Ebay sellers with high profit margins and over 17000 followers can be confident to do a majority of auction sales like this. I have also found SFLmaven jewelry shows up in Google shopping searches high on the lists when searching generically for name brand items and generally they are lower priced than most competitor's same items.
SFLMAVEN HAD A GREAT WEEK WITH 247 SALES> TOTALING $244,548.00 SINCE THE 11th... THAT IS ON TRACK FOR A MILLION DOLLARS IN REVENUE THIS MONTH. AVERAGE OVER $990 PER SALE. PLENTY OF QUALITY STOCK ON THE SHELVES NICE JOB.. $SKDI GREAT WEEK AHEAD!
RECENT SOLD ITEMS
SKDI Oversold ready for huge bounce..
PLUS add for Hakuna sale what does that bring?